Tipsheet
What matters at India’s listed companies
M&A · Pharmaceuticals · Micro cap

Dugar family launches open offer for 26% of Colinz at ₹54/share

A mandatory open offer follows a share purchase agreement for a 34.56% stake, handing control of the nano-cap pharma company to the Dugar family for a combined ₹7.89 crore, over half its market cap.


Mkt cap₹15.11 cr
P/E29.46×
ROE5.24%
Debt / eq.0.07
₹7.89 cr Combined consideration for change of control

What's new

  • Dugar family launches mandatory open offer for up to 26% at ₹54/share, valued at ₹3.54 cr.
  • Separate SPA to acquire 34.56% from promoter at ₹50/share for ₹4.35 cr.
  • Combined transaction at ₹7.89 cr is over half of Colinz's ₹15 cr market cap.

Why this matters

This is a change-of-control event for a nano-cap pharma company. The acquirers, who already held 15.01%, could end up with up to 75.56% post-offer. For a stock with a market cap of just ₹15 crore, the control premium and mandatory offer signal a major shift in ownership and direction.

What we're watching

  • Subscription to the open offer: will existing shareholders tender at ₹54?
  • Delisting prospects: combined stake could cross the 75% threshold.
  • Strategic plans: the Dugar family has not yet disclosed their roadmap for Colinz.

The full read

The Dugar family is buying control of Colinz Laboratories in a two-step transaction. First, a share purchase agreement to acquire 34.56% from promoter Vijaya Mani at ₹50/share for ₹4.35 crore. Then a mandatory open offer for up to 26% at ₹54/share, worth ₹3.54 crore. The combined ₹7.89 crore deal is over half of Colinz's ₹15 crore market cap. The acquirers, Annjana, Likhitta, Antariksh Dugar, and PAC Padam Dugar, held 15.01% before. Post-closing, they could own up to 75.56%. It is a clear change in control. For a nano-cap pharma stock with a trailing P/E of 29.5 and ROE of just 5.2%, the control premium attached to this transaction is substantial relative to its market cap. The open question is what the Dugar family plans to do with a near-76% holding.

Questions answered

Why is the Dugar family making an open offer?
The open offer is mandatory under SEBI SAST regulations because the family is acquiring a 34.56% stake from the existing promoter via a share purchase agreement, triggering a change of control.
What is the total cost of the transaction?
The SPA is valued at ₹4.35 crore (₹50/share for 34.56% stake) and the open offer at ₹3.54 crore (₹54/share for up to 26%). The combined total is approximately ₹7.89 crore, or over 50% of Colinz's ₹15 crore market cap.
How much will the Dugar family own post-offer?
The family already held 15.01% before the deal. If the SPA closes and the open offer is fully subscribed, they could hold up to 75.56% of Colinz.
What is the current market cap and valuation of Colinz?
The market capitalisation is roughly ₹15 crore, with a trailing P/E of 29.5 and ROE of 5.2%. The transaction value of ₹7.89 crore is substantial relative to its size.
Mentioned: Dugar family · Colinz Laboratories · ₹54/share open offer · ₹50/share SPA · Vijaya Mani
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.